{'fraction_non_alphanumeric': 0.07280080889787664, 'fraction_numerical': 0.023255813953488372, 'mean_word_length': 4.32258064516129, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
CHOLESTATIC EFFECTS OF ALUMINUM IN RATS

Aluminum (Al) is found in parenteral nutrition (PN) solutions, accumulating in bone and liver of patients receiving PN therapy. Al is associated with low-turnover osteomalacia PN patients may also develop cholestasis (CS). We studied whether Al could intravenously(IV) 5 mg/kg/d for 14d (Group 1) (n=7) and 7d (Group II) (n=8) and 1 mg/kg/d for 14d (Group III) (n=6). Each group was pair-fed with littermate controls(C) given saline IV. Serum(S) total bile acids(BA), bile flow(BF), and A1 in bile(B) and urine(U) were determined. Results:Biliary BA excretion did not differ among the groups.Rats in Group I had higher SBA vs Group II (p<.05) but no different from Group III. BF in Group I was lower than in Group II (p<.03) and Group III (p<.05). In all groups BA1 excretion was only 3-7% of UA1 excretion. Thus, A1 can produce CS in rats in both a dose and time-related manner and must be considered in the etiology of TPN-associated cholestasis.